A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 28-DAY STUDY OF DEN

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心机构，不一定为研究者机构。本研究旨在研究INS 37217两种剂量规格（20 mg和60 mg）与安慰剂相比的安全性和有效性。安慰剂是一种无菌生理盐水溶液。CF肺病患者将通过雾化器接受研究药物（INS 37217或安慰剂）给药，每日3次，持续28天。希望这项研究将有助于选择适当的剂量，用于在囊性纤维化患者中进行INS 37217的进一步研究。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to investigate the safety and effectiveness of two dose strengths of INS37217, 20 mg and 60 mg, compared to placebo. Placebo is a sterile saline (salt water) solution. The study drug (INS37217 or placebo) will be administered via a nebulizer three times per day for up to 28 days to patients with CF lung disease. It is hoped that this study will help select the appropriate dose for further studies of INS37217 in cystic fibrosis patients.